Physician profile
Gregory L Leischer
NPI 1285770065
$1,069.46
in general payments reported to CMS, 2019-2025
16 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.29 · 2020: $183 · 2021: $124 · 2022: $113 · 2023: $128 · 2024: $349 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $177.18 | 2019-2025 | Total30, Tryptyr, Precision 1 |
| Oyster Point Pharma, INC. | $164.03 | 2023-2024 | Tyrvaya, Ryzumvi |
| Coopervision INC. | $128.49 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| The Walman Optical Company | $117.90 | 2020 | |
| Novartis Pharmaceuticals Corporation | $71.02 | 2020-2022 | |
| Ocular Therapeutix, INC. | $66.51 | 2024 | Dextenza |
| Allergan, INC. | $60.91 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $48.76 | 2021 | |
| Bausch & Lomb Americas INC. | $43.67 | 2022-2024 | Infuse |
| Biotissue Holdings INC. | $37.63 | 2020-2021 | |
| Horizon Therapeutics Plc | $36.89 | 2023 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $29.04 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $24.36 | 2024 | Xdemvy |
| Lombart Brothers, INC. | $23.00 | 2025 | Opd-III |
| Glaukos Corporation | $20.67 | 2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Leischer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.